|
|||||
|
|
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus |
|
| Authors: | L. L. Ilag M. A. Deeg T. Costigan P. Hollander T. C. Blevins S. V. Edelman R. J. Konrad R. A. Ortmann R. K. Pollom W. J. Huster J. S. Zielonka M. J. Prince |
| Affiliation: | 1. Eli Lilly and Company, Indianapolis, IN, USA;2. Baylor Endocrine Center, Dallas, TX, USA;3. Texas Diabetes and Endocrinology, Austin, TX, USA;4. University of California, San Diego, San Diego, CA, USA |
| Abstract: | |
| Keywords: | biosimilar insulin insulin antibody insulin glargine LY2963016 insulin glargine |